Part ofFDA →

FEDERALhearing transcript

High Impact

Congressional Hearing: FDA Oversight of the Infant Formula Shortage

Original title: FDA OVERSIGHT PART II: RESPONSIBILITY FOR THE INFANT FORMULA SHORTAGE

January 1, 2023

FDA infant formula supply chain food safety congressional oversight regulatory compliance

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing examines the federal government's regulatory failures and response timeline regarding the 2022 infant formula crisis, which resulted in nationwide supply shortages for families.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Parents and Caregivers

They experienced limited access to infant formula due to the supply shortage.

Food and Drug Administration

The agency is subject to congressional oversight regarding its regulatory and inspection protocols.

Abbott

The company's manufacturing facility in Sturgis, Michigan, was the subject of FDA inspections and recall actions.

What changed

Last recorded activity January 1, 2023.

What's next

Next step not available in the current record.

Summary

This document is a transcript of a House Subcommittee hearing held on May 11, 2023, to investigate the FDA's response to the infant formula shortage. Lawmakers questioned FDA officials regarding delays in facility inspections, the handling of reports, and the transparency of the agency's internal reviews.

Key Facts

The hearing took place on May 11, 2023, as part of the 118th Congress.
The Subcommittee investigated why it took four months for FDA inspectors to arrive at the Abbott facility in Sturgis, Michigan, after reports of infant illnesses.
The FDA inspected only 3 of 23 infant formula manufacturing facilities in 2023.
Lawmakers questioned the independence of the 'Solomon Report' regarding the FDA's crisis response.
The hearing addressed allegations that the FDA failed to investigate whistleblower warnings.
An 'Infant Formula Timeline' document was submitted by Rep. Grothman.
An FDA inspection report from March 2022 was submitted by Rep. Porter.

Why It Matters

The hearing examines the federal government's regulatory failures and response timeline regarding the 2022 infant formula crisis, which resulted in nationwide supply shortages for families.

Frequently Asked Questions

What was the purpose of this hearing?

To conduct into the FDA's response to the infant formula crisis and determine why the agency was unprepared and slow to act.

What specific facility was discussed?

The Abbott manufacturing facility located in Sturgis, Michigan.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

FDA Inspection Frequency

The hearing highlights a significant gap in FDA oversight, noting that only 3 of 23 infant formula facilities were inspected in 2023.

Food and Drug Administration

Connected Entities

organizationAbbott“Manufacturer of infant formula with a facility in Sturgis, Michigan”Map →

personLisa McClain“Chairwoman of the Subcommittee on Health Care and Financial Services”Map →

personRobert Califf“FDA Commissioner”Map →

personSusan T. Mayne“Director, Center for Food Safety and Applied Nutrition, FDA”Map →

personFrank Yiannas“Former Deputy Commissioner, Office of Food Policy and Response”Map →

organizationFood and Drug Administration“Federal agency under oversight”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance85
How much this matters to a regular citizen
Controversy75
Intensity of disagreement among stakeholders
Entertainment40
Compellingness for a non-policy-wonk reader
Buzz30
Current news / social attention level

Publisher tools